Clinical Trials Logo

Encephalitis, Japanese clinical trials

View clinical trials related to Encephalitis, Japanese.

Filter by:

NCT ID: NCT00735644 Completed - Hepatitis A Clinical Trials

Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi pasteur. Secondary objective: To describe the safety of vaccination in all subjects

NCT ID: NCT00694460 Completed - Rabies Clinical Trials

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses. Rabies vaccination with PCECV did not interfere with the antibody response to Japanese encephalitis vaccine. The rabies vaccine PCECV and Japanese encephalitis vaccine are safe and immunogenic when administered concomitantly to toddlers.

NCT ID: NCT00621764 Completed - Hepatitis A Clinical Trials

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.

NCT ID: NCT00605085 Completed - Clinical trials for Japanese Encephalitis

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years

NCT ID: NCT00604708 Completed - Clinical trials for Japanese Encephalitis

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged > or = 18 years

NCT ID: NCT00596271 Completed - Clinical trials for Japanese Encephalitis

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440

NCT ID: NCT00596102 Completed - Clinical trials for Japanese Encephalitis

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Start date: October 2005
Phase: Phase 3
Study type: Observational

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.

NCT ID: NCT00595790 Completed - Clinical trials for Japanese Encephalitis

Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged > or = 18 years

NCT ID: NCT00595465 Completed - Clinical trials for Japanese Encephalitis

Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The objective is to demonstrate equivalence of three commercial IC51 batches in terms of geometric mean titers for anti-JEV neutralizing antibody

NCT ID: NCT00595309 Completed - Clinical trials for Japanese Encephalitis

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.